Document is current

Article History

Received: 12 November 2023

Accepted: 3 January 2024

First Online: 12 February 2024

Declarations

:

: Dr. Iryna Kuchuk reports personal fee from: Eli-Lilly (Honorarium and consulting), Novartis (Honorarium and consulting), Pfizer (Honorarium and consulting), Rhenium Oncotest (Honorarium and consulting), all outside the submitted manuscript. Dr. Alberto Gabizon reports consultant fees from Innomedica (Switzerland) and Lipomedix (Israel), and receives grant support from MSD (USA), all outside the submitted manuscript. Dr. Rinat Yerushalmi reports personal fee from: Roche (Consulting, invited speaker, Research grant), Pfizer (Consulting), Novartis (Consulting, Invited speaker), Rhenium (Consulting)), Medison (Invited speaker), MSD (Invited speaker), Astra-Zeneca (Invited speaker), Eli Lilly ( Consulting, Invited Speaker), Gilead (Consulting), Stemline (Invited speaker, Consulting), all outside the submitted manuscript. Dr. Hadar Goldvaser reports personal fee from: AstraZeneca (Honorarium), Gilead (Honorarium and consulting), Eli-Lilly (Honorarium and consulting), MSD (Honorarium and consulting), Novartis (Honorarium and consulting), Pfizer (Honorarium and consulting), Roche (Honorarium), Rhenium Oncotest (Honorarium and consulting), all not related to the submitted manuscript. All other authors have no conflicts of interest.

: This is a retrospective study. The study was approved by the Helsinki Committee of both Rabin Medical Center (0727–19-RMC, January 2020) and Meir Medical Center (0205–20-MMC).

: As this was a chart review retrospective study the Ethics Committees has confirmed that informed consent is not required.

: Not relevant.